Specific Effect of BRAF-Inhibitors on a BRAF-mutant and a Wild-type Cell Line of Malignant Melanoma

被引：0
|
作者：
Steck, M. [1 ]
Grabenbauer, M. [1 ]
Fuenfle, R. [1 ]
Hecht, M. [1 ]
Fietkau, R. [1 ]
Distel, L., V [1 ]
机构：
[1] Friedrich Alexander Univ Erlangen Nurnberg, Strahlenklin, Erlangen, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2017年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P22-5-jD
引用
收藏
页码：S169 / S170
页数：2
相关论文
共 50 条
  • [31] Combination of MEK and PI3K inhibition in BRAF wild-type and mutant melanoma
    Zhang, Yanping
    Peng, Guangyong
    Hsueh, Eddy C.
    CANCER RESEARCH, 2016, 76
  • [32] Salinomycin, an anti-cancer stem cell antibiotic, overcomes acquired resistance to BRAF inhibitors in BRAF-mutant human melanoma cell lines.
    Crespo, Daniel
    Pulido, Ines
    Rodriguez, Maria L.
    Aparisi, Salvador
    Lopez, Alejandro
    Soucheray, Margaret
    Al-Shahrour, Fatima
    Shimamura, Takeshi
    Ortega, Angel
    Carretero, Julian
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [33] NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth
    Kaoud, Tamer S.
    Mohassab, Aliaa M.
    Hassan, Heba A.
    Yan, Chunli
    Van Ravenstein, Sabrina X.
    Abdelhamid, Dalia
    Dalby, Kevin N.
    Abdel-Aziz, Mohamed
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 186
  • [34] What Is Optimal First-Line Treatment of Unresectable or Advanced BRAF-Mutant Melanoma?
    Atkins, Michael B.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (06) : 417 - 419
  • [35] Trees, Forests, and Other Implications of a BRAF Mutant Gene Signature in Patients With BRAF Wild-Type Disease
    Faris, Jason E.
    Ryan, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (12) : 1255 - 1257
  • [36] Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Deborah JL Wong
    Lidia Robert
    Mohammad S Atefi
    Amanda Lassen
    Geetha Avarappatt
    Michael Cerniglia
    Earl Avramis
    Jennifer Tsoi
    David Foulad
    Thomas G Graeber
    Begonya Comin-Anduix
    Ahmed Samatar
    Roger S Lo
    Antoni Ribas
    Molecular Cancer, 13
  • [37] Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Wong, Deborah J. L.
    Robert, Lidia
    Atefi, Mohammad S.
    Lassen, Amanda
    Avarappatt, Geetha
    Cerniglia, Michael
    Avramis, Earl
    Tsoi, Jennifer
    Foulad, David
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Samatar, Ahmed
    Lo, Roger S.
    Ribas, Antoni
    MOLECULAR CANCER, 2014, 13
  • [38] BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature
    Lengyel, Krisztina
    Young, Fergus
    Kucukmetin, Ali
    Cresti, Nicola
    Plummer, Ruth
    Ralte, Angela
    O'Donnell, Rachel Louise
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2020, 39 (04) : 321 - 326
  • [39] Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
    Ebinc, Senar
    Kalkan, Ziya
    Oruc, Zeynep
    Sezgin, Yasin
    Urakci, Zuhat
    Kucukoner, Mehmet
    Kaplan, Muhammet Ali
    Isikdogan, Abdurrahman
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2023, 57 (03): : 77 - 82
  • [40] Choice of immunotherapy vs. targeted therapy in first line treatment for BRAF-mutant melanoma
    Long, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 5 - 5
12345